Background: A single nucleotide polymorphism is identified at CCNE1 and RIP2. We evaluated the relationship between the CCNE1 or RIP2 and the risk, clinic stage and pathologic grade of bladder cancer. Methods: Peripheral venous blood samples were obtained from 176 patients with bladder cancer and 210 controls with no cancers of any kinds. The diagnoses, pathological stage of bladder cancer were all determined according to the pathological reports of transurethral bladder cancer resection and radical cystectomy. The polymorphism was determined by polymerase chain reaction and sequencing methods. Results: (I) The distribution of the CCNE1 and RIP 2 allele frequencies among control subjects was in HardyWeinberg equilibrium; (II) the frequency of CCNE1 (rs8102137) variant allele was significantly higher in the case subjects (40.91%) than in controls (30.95%) (P<0.05, OR=1.54, 95% CI 1.02-2.45). The frequency of CCNE1(rs8102137) variant allele was significantly higher in the case subjects (72.73%) than in controls (62.38%) (P<0.05, OR=1.61, 95% CI, 1.04-2.48); (III) there was no association between the CCNE1 (rs8102137) and RIP2 (rs42490). Polymorphisms and Pathological grade and clinical stage of bladder cancer. Conclusions: The CCNE1 (rs8102137) and RIP2 (rs42490) polymorphism have interaction in occurrence of bladder cancer process, no association with Pathological grade and clinical stage of bladder cancer.
Background: A single nucleotide polymorphism is identified at CCNE1 and RIP2. We evaluated the relationship between the CCNE1 or RIP2 and the risk, clinic stage and pathologic grade of bladder cancer. Methods: Peripheral venous blood samples were obtained from 176 patients with bladder cancer and 210 controls with no cancers of any kinds. The diagnoses, pathological stage of bladder cancer were all determined according to the pathological reports of transurethral bladder cancer resection and radical cystectomy. The polymorphism was determined by polymerase chain reaction and sequencing methods. Results: (I) The distribution of the CCNE1 and RIP 2 allele frequencies among control subjects was in HardyWeinberg equilibrium; (II) the frequency of CCNE1 (rs8102137) variant allele was significantly higher in the case subjects (40.91%) than in controls (30.95%) (P<0.05, OR=1.54, 95% CI 1.02-2.45). The frequency of CCNE1(rs8102137) variant allele was significantly higher in the case subjects (72.73%) than in controls (62.38%) (P<0.05, OR=1.61, 95% CI, 1.04-2.48); (III) there was no association between the CCNE1 (rs8102137) and RIP2 (rs42490 Background: Dysregulation of apoptotic pathway plays a critical role in tumor progression and resistance to chemo-, immuno-and radio-therapy in human renal cell carcinoma (RCC). The X-linked Inhibitor of Apoptosis (XIAP), a key member of the Inhibitors of Apoptosis Protein (IAP) family, possesses the most potential to inhibit apoptosis by directly binding the initiator caspase-9, -3 and -7, thereby promoting tumor cell survival during tumor progression and numerous anticancer therapies. Methods: We investigated the difference of XIAP basal expression level and evaluated its contribution to the resistance to apoptosis in RCC cell lines exposed to apoptosis-inducing drugs by histological methods and western blot analysis, than through RNAi, we got downregulation XIAP expression clone no.2 cells, and observed its contribution to the sensitivity to apoptosis induced through Intrinsic pathway. Results: The different levels of XIAP expression could be detected in RCC cell lines between ClearCa-2 and ClearCa-6. CleraCa-6 with lower expression of XIAP much more sensitive to the apoptotic induced by means of death receptor and mitochondria pathway and NF-κB inhibition than ClearCa-2 with higher expression of XIAP(P<0.05). Downregulation of XIAP expression was observed in both cell lines by NF-κB inhibitor and in ClearCa-6 by the apoptotic induction mediated by mitochondria pathway. However, there existed the observed different levels of XIAP expression in ClearCa-2 and ClearCa-6 cell lines all along during the apoptotic inductions. Further, no-expression of XIAP cell line-clone no.2 was transfected, and it was more sensitive to the apoptosis inductions by mitochondria pathway.
